Albion Financial Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Albion Financial Group’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42	Hold	7	–	–	﹤0.01%	640
2026 Q1	$23	Hold	7	–	–	﹤0.01%	728
2025 Q4	$53	Hold	7	–	–	﹤0.01%	642
2025 Q3	$24	Hold	7	–	–	﹤0.01%	645
2025 Q2	$22	Hold	7	–	–	﹤0.01%	581
2025 Q1	$22	Hold	7	–	–	﹤0.01%	603
2024 Q4	$17	Hold	7	–	–	﹤0.01%	677
2024 Q3	$20	Hold	7	–	–	﹤0.01%	505
2024 Q2	$21	Hold	7	–	–	﹤0.01%	508
2024 Q1	$21	Hold	7	–	–	﹤0.01%	497
2023 Q4	$18	Hold	7	–	–	﹤0.01%	470
2023 Q3	$22	Sell	7 -1	-13%	-$4	﹤0.01%	473
2023 Q2	$35	Hold	8	–	–	﹤0.01%	465
2023 Q1	$54	Hold	8	–	–	﹤0.01%	439
2022 Q4	$49	Hold	8	–	–	﹤0.01%	478
2022 Q3	$0	Hold	8	–	–	﹤0.01%	533
2022 Q2	$0	Hold	8	–	–	﹤0.01%	594
2022 Q1	$0	Hold	8	–	–	﹤0.01%	645
2021 Q4	$0	Hold	8	–	–	﹤0.01%	668
2021 Q3	$1K	Hold	8	–	–	﹤0.01%	498
2021 Q2	$1K	Buy	+8	New	+$781	﹤0.01%	494
2020 Q4	$0	Buy	+8	New	+$294	﹤0.01%	499

Other funds holding IMDX

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

PSB

Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Albion Financial Group's IMDX Position: Q2 2026 in Review

Albion Financial Group held its Insight Molecular Diagnostics (IMDX) position steady in Q2 2026 at 7 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #640.

Albion Financial Group first reported a position in IMDX in Q4 2020 and has held it in 22 quarters since. The position peaked at $1K in Q3 2021. 6 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

Albion Financial Group held 7 shares of Insight Molecular Diagnostics worth $42 as of Q2 2026.
Albion Financial Group left its Insight Molecular Diagnostics share count unchanged in Q2 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Albion Financial Group's portfolio in Q2 2026, its #640 holding.
Albion Financial Group first reported a position in Insight Molecular Diagnostics in Q4 2020 and has held it in 22 quarters since.
Albion Financial Group's Insight Molecular Diagnostics position peaked at $1K in Q3 2021.
6 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Albion Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.